FDA Resolves Cancer Drug Cisplatin Shortage

1. Cisplatin Shortage Resolved: The FDA has announced that the cancer drug cisplatin is no longer in shortage, with supply levels returning to nearly 100% of pre-shortage levels.
2. Collaboration with Manufacturers: The FDA worked closely with manufacturers to boost production capacity and import additional supplies to alleviate the shortage.
3. Importation of Cisplatin: The FDA allowed the importation of cisplatin from an FDA-registered facility outside the U.S. and from Chinese manufacturer Qilu Pharmaceutical to supplement the domestic supply.
4. Impact on Patients: The shortage had significant implications for cancer patients, with some being forced to receive alternative treatments, such as carboplatin, which is considered less effective for certain conditions.
5. Ongoing Efforts: Despite the resolution of the cisplatin shortage, the FDA continues to work with manufacturers to address ongoing shortages of other cancer drugs, including carboplatin and methotrexate.